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During this period, the studies were concerned primarily with substance P, bradykinin, angiotensin, ACTH, MSH, and vasopressin. Studies on substance P were discussed in part I, so now the other peptides will be discussed.
Bradykinin
It has already been mentioned that studies of the neurotropic effects of substance P stimulated research on the CNS effects of many other peptides. M. Rocha e Silva and his co-workers studied the central effects of intraventricular injections of bradykinin as early as 1959. They observed that such injections had a tranquilizing effect and if higher doses were used, the animals became catatonic. In 1963-1969 it was shown in the same laboratory that central injections of bradykinin also stimulated respiration, caused bradycardia, affected the EEG, and excited fast and slow nociceptive fibers (74, 163) . In the early 1960s R. Capek demonstrated typical central nervous system effects of purified and synthetic bradykinin in cats and mice: excitation, stereotypic behavior, balance impairment, and catatonia (32). At the same time W. Krivoy found that bradykinin affected synaptic transmission (90). J. P. Buckley et al. (29) and F. Guzman, C. Braun, and R. K. S. Lim (77) also showed that bradykinin and angiotensin had central nervous effects (particularly affecting the cardiovascular system) after intravenous, intracarotid, or intraventricular injection. By 1970, it was established that bradykinin can act directly on the central nervous system, causing neurotropic and behavioral effects. FRONTIERS IN NEUROENDOCRINOLOGY 17, 155-179 (1996) ARTICLE NO. 0004
